$XNCR
Xencor Inc

2021 Form 10-K Financial Statement

#000155837022001969 Filed on February 24, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020
Revenue $275.1M $41.85M $122.7M
YoY Change 124.21% 1090.39% -21.7%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $38.84M $7.600M $29.70M
YoY Change 30.76% 13.43% 22.22%
% of Gross Profit
Research & Development $192.5M $47.90M $169.8M
YoY Change 13.37% 75.46% 43.18%
% of Gross Profit
Depreciation & Amortization $7.491M $1.500M $5.794M
YoY Change 29.29% 25.0% 34.81%
% of Gross Profit
Operating Expenses $231.3M $55.60M $199.5M
YoY Change 15.97% 63.05% 39.63%
Operating Profit $43.77M -$13.70M -$76.80M
YoY Change -156.99% -55.19% -655.53%
Interest Expense $40.14M $700.0K $7.300M
YoY Change 449.84% -79.41% -46.32%
% of Operating Profit 91.71%
Other Income/Expense, Net $38.86M -$700.0K $7.464M
YoY Change 420.69% -44.14%
Pretax Income $82.63M -$13.70M -$69.33M
YoY Change -219.18% -49.63% -355.02%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $82.63M -$13.69M -$69.33M
YoY Change -219.18% -49.13% -357.98%
Net Earnings / Revenue 30.04% -32.71% -56.51%
Basic Earnings Per Share $1.42 -$0.24 -$1.21
Diluted Earnings Per Share $1.37 -$0.24 -$1.21
COMMON SHARES
Basic Shares Outstanding 58.38M 57.46M 57.21M
Diluted Shares Outstanding 60.50M 57.21M

Balance Sheet

Concept 2021 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $334.1M $603.0M $603.0M
YoY Change -44.59% 13.82% 13.82%
Cash & Equivalents $143.5M $163.5M $163.5M
Short-Term Investments $190.6M $439.5M $439.5M
Other Short-Term Assets $23.88M $10.70M $10.70M
YoY Change 123.15% 64.62% 64.62%
Inventory
Prepaid Expenses
Receivables $66.38M $11.44M $23.90M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $424.4M $637.7M $637.7M
YoY Change -33.45% 14.2% 14.2%
LONG-TERM ASSETS
Property, Plant & Equipment $59.97M $21.68M $32.30M
YoY Change 85.67% 37.18% 28.17%
Goodwill
YoY Change
Intangibles $15.98M
YoY Change 10.79%
Long-Term Investments $331.7M $17.10M $17.10M
YoY Change 1839.92% -76.08% -76.08%
Other Assets $653.0K $212.0K $200.0K
YoY Change 226.5% -31.83% -33.33%
Total Long-Term Assets $413.8M $65.57M $65.50M
YoY Change 531.82% -41.37% -41.47%
TOTAL ASSETS
Total Short-Term Assets $424.4M $637.7M $637.7M
Total Long-Term Assets $413.8M $65.57M $65.50M
Total Assets $838.2M $703.2M $703.2M
YoY Change 19.2% 4.92% 4.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.00M $8.954M $9.000M
YoY Change 55.57% -12.12% -11.76%
Accrued Expenses $19.44M $17.60M $19.50M
YoY Change -0.29% 95.7% 74.11%
Deferred Revenue $92.62M
YoY Change 104.9%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $70.74M $121.1M $121.1M
YoY Change -41.59% 81.89% 81.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $33.97M $9.700M $9.700M
YoY Change 250.2% -7.62% -7.62%
Total Long-Term Liabilities $33.97M $9.700M $9.700M
YoY Change 250.2% -7.62% -7.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $70.74M $121.1M $121.1M
Total Long-Term Liabilities $33.97M $9.700M $9.700M
Total Liabilities $104.7M $130.8M $130.8M
YoY Change -19.95% 69.76% 69.87%
SHAREHOLDERS EQUITY
Retained Earnings -$365.7M
YoY Change 23.39%
Common Stock $580.0K
YoY Change 1.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $733.5M $572.4M $572.4M
YoY Change
Total Liabilities & Shareholders Equity $838.2M $703.2M $703.2M
YoY Change 19.2% 4.92% 4.91%

Cashflow Statement

Concept 2021 2020 Q4 2020
OPERATING ACTIVITIES
Net Income $82.63M -$13.69M -$69.33M
YoY Change -219.18% -49.13% -357.98%
Depreciation, Depletion And Amortization $7.491M $1.500M $5.794M
YoY Change 29.29% 25.0% 34.81%
Cash From Operating Activities -$16.85M $17.10M -$5.004M
YoY Change 236.79% -187.24% -107.77%
INVESTING ACTIVITIES
Capital Expenditures $13.30M -$4.300M $10.54M
YoY Change 26.19% 19.44% 43.33%
Acquisitions
YoY Change
Other Investing Activities -$30.27M $83.10M $114.0M
YoY Change -126.56% 328.35% -385.4%
Cash From Investing Activities -$46.25M $78.80M $100.2M
YoY Change -146.16% 401.91% -296.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $28.92M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 43.04M 9.500M 18.04M
YoY Change 138.52% 216.67% 69.24%
NET CHANGE
Cash From Operating Activities -16.85M 17.10M -5.004M
Cash From Investing Activities -46.25M 78.80M 100.2M
Cash From Financing Activities 43.04M 9.500M 18.04M
Net Change In Cash -20.06M 105.4M 113.2M
YoY Change -117.72% -11811.11% 370.51%
FREE CASH FLOW
Cash From Operating Activities -$16.85M $17.10M -$5.004M
Capital Expenditures $13.30M -$4.300M $10.54M
Free Cash Flow -$30.15M $21.40M -$15.54M
YoY Change 93.99% -233.75% -127.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
57873444
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59355558
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 xncr Defined Contribution Plan Annual Vesting Percentage Over Vesting Term
DefinedContributionPlanAnnualVestingPercentageOverVestingTerm
0.33
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001326732
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-36182
CY2021 dei Entity Registrant Name
EntityRegistrantName
Xencor, Inc
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-1622502
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
111 West Lemon Avenue
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Monrovia
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
91016
CY2021 dei City Area Code
CityAreaCode
626
CY2021 dei Local Phone Number
LocalPhoneNumber
305-5900
CY2021 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2021 dei Trading Symbol
TradingSymbol
XNCR
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
2000288972
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59375320
CY2021 dei Auditor Firm
AuditorFirmId
49
CY2021 dei Auditor Name
AuditorName
RSM US LLP
CY2021 dei Auditor Location
AuditorLocation
Los Angeles, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
143480000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163544000
CY2021Q4 us-gaap Debt Securities Current
DebtSecuritiesCurrent
153767000
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
12500000
CY2020Q4 us-gaap Debt Securities Current
DebtSecuritiesCurrent
434156000
CY2021Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
36860000
CY2020Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
5303000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
66384000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11443000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23877000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10726000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
424368000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
637672000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28240000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
838211000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
733504000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
572444000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21682000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16493000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15977000
CY2021Q4 us-gaap Debt Securities Noncurrent
DebtSecuritiesNoncurrent
300465000
CY2020Q4 us-gaap Debt Securities Noncurrent
DebtSecuritiesNoncurrent
1030000
CY2021Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
31262000
CY2020Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
16071000
CY2021Q4 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
5000000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
31730000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10600000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
653000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
212000
CY2021Q4 us-gaap Assets
Assets
838211000
CY2020Q4 us-gaap Assets
Assets
703244000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14001000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8954000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19443000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17603000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1889000
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
37294000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
92615000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
70738000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
121061000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33969000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9739000
CY2021Q4 us-gaap Liabilities
Liabilities
104707000
CY2020Q4 us-gaap Liabilities
Liabilities
130800000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
703244000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
275111000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59355558
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
57873444
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
595000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
580000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1017523000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
937525000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1510000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
74000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-283104000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-365735000
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57212737
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58467880
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
312000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
82631000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-69333000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
26875000
CY2021 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1584000
CY2020 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1087000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
122694000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
156700000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
192507000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
169802000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
118590000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38837000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29689000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24286000
CY2021 us-gaap Operating Expenses
OperatingExpenses
231344000
CY2020 us-gaap Operating Expenses
OperatingExpenses
199491000
CY2019 us-gaap Operating Expenses
OperatingExpenses
142876000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
43767000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-76797000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
13824000
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
849000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7264000
CY2019 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
13619000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1274000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
95000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-256000
CY2021 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
39289000
CY2020 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
105000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
38864000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7464000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13363000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
82631000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69333000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
27187000
CY2019 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
2132000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
81047000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70420000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
29007000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.42
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.48
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.37
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.46
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58379641
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57212737
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56531439
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60495455
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
521681000
CY2019 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
9269000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1393000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
29007000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31851000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
593201000
CY2020 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
16617000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58379641
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57212737
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1427000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70420000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31619000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
572444000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28920000
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
12281000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1837000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
81047000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
36975000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
733504000
CY2021 us-gaap Profit Loss
ProfitLoss
82631000
CY2020 us-gaap Profit Loss
ProfitLoss
-69333000
CY2019 us-gaap Profit Loss
ProfitLoss
26875000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7491000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5794000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4298000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3160000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
272000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4321000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
36975000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
31619000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
31851000
CY2021 us-gaap Noncash Project Abandonment Costs
NoncashProjectAbandonmentCosts
934000
CY2020 us-gaap Noncash Project Abandonment Costs
NoncashProjectAbandonmentCosts
535000
CY2019 us-gaap Noncash Project Abandonment Costs
NoncashProjectAbandonmentCosts
221000
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-462000
CY2020 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-4000
CY2019 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-8000
CY2020 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
153000
CY2021 xncr Noncash Consideration Received From Revenue Contracts
NoncashConsiderationReceivedFromRevenueContracts
22379000
CY2020 xncr Noncash Consideration Received From Revenue Contracts
NoncashConsiderationReceivedFromRevenueContracts
26660000
CY2021 xncr Equity Received In Connection With Sale Of Financial Assets
EquityReceivedInConnectionWithSaleOfFinancialAssets
3300000
CY2020 xncr Cash Redemption Of Equity Received In Connection With Agreement
CashRedemptionOfEquityReceivedInConnectionWithAgreement
5390000
CY2021 us-gaap Equity Securities Fv Ni Unrealized Gain
EquitySecuritiesFvNiUnrealizedGain
20988000
CY2020 us-gaap Equity Securities Fv Ni Unrealized Gain
EquitySecuritiesFvNiUnrealizedGain
105000
CY2021 us-gaap Impairment Of Investments
ImpairmentOfInvestments
762000
CY2021 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
54941000
CY2020 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-10131000
CY2019 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
11321000
CY2021 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
-655000
CY2020 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
-1190000
CY2019 us-gaap Increase Decrease In Accrued Investment Income Receivable
IncreaseDecreaseInAccruedInvestmentIncomeReceivable
387000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13151000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4170000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3828000
CY2020 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-895000
CY2019 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-704000
CY2021 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-12059000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1235000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6392000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60495455
CY2020 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
12401000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5047000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1840000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8608000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-667000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
45484000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7052000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16853000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5004000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
64374000
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
485152000
CY2019 xncr Increase Decrease In Lease Liabilities And Right Of Use Assets
IncreaseDecreaseInLeaseLiabilitiesAndRightOfUseAssets
1354000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-55321000
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2682000
CY2020 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
3229000
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
3685000
CY2019 xncr Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-1513000
CY2021 xncr Increase Decrease In Lease Liabilities And Right Of Use Assets
IncreaseDecreaseInLeaseLiabilitiesAndRightOfUseAssets
1211000
CY2020 xncr Increase Decrease In Lease Liabilities And Right Of Use Assets
IncreaseDecreaseInLeaseLiabilitiesAndRightOfUseAssets
-325000
CY2020 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
757617000
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
456923000
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
19000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
509597000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
643658000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
496855000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13299000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10539000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7353000
CY2021 us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
5000000
CY2021 xncr Exercise Of Stock Options Investing Activity
ExerciseOfStockOptionsInvestingActivity
842000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-46249000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
100192000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50970000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
12281000
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
16617000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
9269000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1837000
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1427000
CY2019 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1393000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28920000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43038000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18044000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10662000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20064000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
113232000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24066000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163544000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50312000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26246000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143480000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
163544000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
50312000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
14000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
15000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
11000
CY2019 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
400000
CY2021 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1584000
CY2020 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-1087000
CY2019 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
2132000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, other comprehensive gain (loss) and the related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to its accrued clinical trial and manufacturing development expenses, stock-based compensation expense, evaluation of intangible assets, investments, leases and other assets for evidence of impairment, fair value measurements, and contingencies. Significant estimates in these financial statements include estimates made for royalty revenue, accrued research and development expenses, stock-based compensation expenses, intangible assets, incremental borrowing rate for right-of-use asset and lease liability, estimated standalone selling price of performance obligations, estimated time for completing delivery of performance obligations under certain arrangements, the likelihood of recognizing variable consideration, the carrying value of equity instruments without a readily determinable fair value, and recoverability of deferred tax assets.</p>
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
37300000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
92600000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7273000
CY2020 xncr Marketable Securities Impairment Losses And Recoveries
MarketableSecuritiesImpairmentLossesAndRecoveries
0
CY2021 xncr Marketable Securities Impairment Losses And Recoveries
MarketableSecuritiesImpairmentLossesAndRecoveries
0
CY2021Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
800000
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1400000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentrations of Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents, and marketable debt securities are financial instruments that potentially subject the Company to concentrations of risk. We invest our cash in corporate debt securities and U.S. sponsored agencies with strong credit ratings. We have established guidelines relative to diversification and maturities that are designed to help ensure safety and liquidity. These guidelines are periodically reviewed to take advantage of trends in yields and interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents are maintained at financial institutions, and at times, balances may exceed federally insured limits. We have never experienced any losses related to these balances. Amounts on deposit in excess of federally insured limits at December 31, 2021 and 2020 approximated $143.2 million and $163.3 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We have payables with four service providers that represent 64% of our total payables and with one service provider that represented 49% of our total payables at December 31, 2021 and 2020, respectively. We rely on four critical suppliers for the manufacture of our drug product for use in our clinical trials. While we believe that there are </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">alternative vendors available, a change in manufacturing vendors could cause a delay in the availability of drug product and result in a delay of conducting and completing our clinical trials. No other vendor accounted for more than 10% of total payables at December 31, 2021 or 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have receivables with two service providers that represent 84% and 88% of our total receivables at December 31, 2021 and 2020, respectively. The receivables are related to royalty revenues from our licensing and collaboration agreements. No other customer accounted for more than 10% of total receivables at December 31, 2021 or 2020.</p>
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
143200000
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
163300000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1073000
CY2021 xncr Number Of Primary Criterias To Determine Capitalization Of Patent
NumberOfPrimaryCriteriasToDetermineCapitalizationOfPatent
3
CY2021 us-gaap Noncash Project Abandonment Costs
NoncashProjectAbandonmentCosts
900000
CY2020 us-gaap Noncash Project Abandonment Costs
NoncashProjectAbandonmentCosts
500000
CY2019 us-gaap Noncash Project Abandonment Costs
NoncashProjectAbandonmentCosts
200000
CY2021Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
24925000
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
23429000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
16493000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
15977000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1200000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
900000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
957000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
770000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
680000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
586000
CY2021Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
3207000
CY2021 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2115814
CY2019 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1936441
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
37000000.0
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31600000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31900000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
82631000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-69333000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
26875000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58379641
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57212737
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56531439
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.42
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.21
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.48
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
82631000
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-69333000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
26875000
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56531439
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57212737
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58467880
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.37
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.21
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.46
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1196268
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1022623
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 xncr Cash And Cash Equivalents And Marketable Securities Amortized Cost
CashAndCashEquivalentsAndMarketableSecuritiesAmortizedCost
579624000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1501000
CY2021Q4 us-gaap Investments
Investments
578124000
CY2021Q4 us-gaap Investments
Investments
578124000
CY2020Q4 xncr Cash And Cash Equivalents And Marketable Securities Amortized Cost
CashAndCashEquivalentsAndMarketableSecuritiesAmortizedCost
594038000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
94000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9000
CY2020Q4 us-gaap Investments
Investments
594123000
CY2020Q4 us-gaap Investments
Investments
594123000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
153871000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
153767000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
301861000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
300465000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
455732000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
454232000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
90246000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
105000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
300465000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
1396000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
56645000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
9000
CY2021 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
39289000
CY2020 us-gaap Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
105000
CY2021 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
18301000
CY2020 us-gaap Equity Securities Fv Ni Realized Gain Loss
EquitySecuritiesFvNiRealizedGainLoss
801000
CY2021 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
20988000
CY2020 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-696000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
51068000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
38713000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22828000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17031000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28240000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21682000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6300000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4700000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3400000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
17352000
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-14559000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
5709000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
783000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-4659000
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
2549000
CY2021 xncr Income Tax Reconciliation Research And Development Credit
IncomeTaxReconciliationResearchAndDevelopmentCredit
-10492000
CY2020 xncr Income Tax Reconciliation Research And Development Credit
IncomeTaxReconciliationResearchAndDevelopmentCredit
-9669000
CY2019 xncr Income Tax Reconciliation Research And Development Credit
IncomeTaxReconciliationResearchAndDevelopmentCredit
-6747000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2424000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
529000
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1927000
CY2019 xncr Effective Income Tax Rate Reconciliation Tax Credit State Amount
EffectiveIncomeTaxRateReconciliationTaxCreditStateAmount
-1725000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
95000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
288000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
151000
CY2021Q4 us-gaap Deferred Tax Liabilities Other Comprehensive Income
DeferredTaxLiabilitiesOtherComprehensiveIncome
3824000
CY2020Q4 us-gaap Deferred Tax Liabilities Other Comprehensive Income
DeferredTaxLiabilitiesOtherComprehensiveIncome
24000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
11200000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
56000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-301000
CY2021 xncr Effective Income Tax Rate Reconciliation Change In State Rate Amount
EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount
2599000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-12761000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
28302000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-4550000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
312000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
46629000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
56182000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
48128000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
38047000
CY2021Q4 us-gaap Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross
DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross
327000
CY2020Q4 us-gaap Deferred Tax Assets Unrealized Losses On Availablefor Sale Securities Gross
DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross
195000
CY2021Q4 xncr Deferred Tax Assets Capitalized Lease Assets
DeferredTaxAssetsCapitalizedLeaseAssets
489000
CY2020Q4 xncr Deferred Tax Assets Capitalized Lease Assets
DeferredTaxAssetsCapitalizedLeaseAssets
288000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
9207000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
8464000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
11925000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
104780000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
115101000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
93580000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
105995000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
11200000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
9106000
CY2021Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts
3416000
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Patent Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedPatentCosts
4219000
CY2021Q4 xncr Deferred Tax Liabilities Equity Investment
DeferredTaxLiabilitiesEquityInvestment
3508000
CY2020Q4 xncr Deferred Tax Liabilities Equity Investment
DeferredTaxLiabilitiesEquityInvestment
4497000
CY2021Q4 xncr Deferred Tax Liabilities License Costs
DeferredTaxLiabilitiesLicenseCosts
151000
CY2020Q4 xncr Deferred Tax Liabilities License Costs
DeferredTaxLiabilitiesLicenseCosts
194000
CY2021Q4 xncr Deferred Tax Liabilities Capitalized Legal Costs
DeferredTaxLiabilitiesCapitalizedLegalCosts
13000
CY2020Q4 xncr Deferred Tax Liabilities Capitalized Legal Costs
DeferredTaxLiabilitiesCapitalizedLegalCosts
21000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
9106000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-12400000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
36975000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
31619000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
31851000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
36975000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
31619000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
31851000
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
8676329
CY2021 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y7M24D
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
29.11
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
5576430
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
24.15
CY2021 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2097000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5566000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
5713000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5817000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
5279000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
52117000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
76589000
CY2021Q4 xncr Lessee Operating Lease Liability Tenant Allowance
LesseeOperatingLeaseLiabilityTenantAllowance
17032000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25588000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
33969000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
33969000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
4342000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
2503000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
2596000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
58000
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
150000
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
80000
CY2021 us-gaap Lease Cost
LeaseCost
4400000
CY2020 us-gaap Lease Cost
LeaseCost
2653000
CY2019 us-gaap Lease Cost
LeaseCost
2676000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
2773000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
2233000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
1929000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12Y3M18D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M24D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.058
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.055
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.055
CY2021 xncr Defined Contribution Plan Vesting Period
DefinedContributionPlanVestingPeriod
P3Y
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
1100000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
275100000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
122700000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
156700000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
275100000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
122700000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
156700000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
275100000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
122700000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
156700000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
37300000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
92600000
CY2018Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.035
CY2020Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.040
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
800000
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
600000

Files In Submission

Name View Source Status
0001558370-22-001969-index-headers.html Edgar Link pending
0001558370-22-001969-index.html Edgar Link pending
0001558370-22-001969.txt Edgar Link pending
0001558370-22-001969-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xncr-20211231.xsd Edgar Link pending
xncr-20211231x10k.htm Edgar Link pending
xncr-20211231x10k004.jpg Edgar Link pending
xncr-20211231x10k_htm.xml Edgar Link completed
xncr-20211231xex10d38.htm Edgar Link pending
xncr-20211231xex10d39.htm Edgar Link pending
xncr-20211231xex23d1.htm Edgar Link pending
xncr-20211231xex31d1.htm Edgar Link pending
xncr-20211231xex31d2.htm Edgar Link pending
xncr-20211231xex32d1.htm Edgar Link pending
xncr-20211231xex32d2.htm Edgar Link pending
xncr-20211231_cal.xml Edgar Link unprocessable
xncr-20211231_def.xml Edgar Link unprocessable
xncr-20211231_lab.xml Edgar Link unprocessable
xncr-20211231_pre.xml Edgar Link unprocessable